HOME >> MEDICINE >> NEWS
Where do new therapies work best?

An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".

The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.

The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related medicine news :

1. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
2. Where is the most dangerous place to travel over the holiday?
3. Where should I have my outpatient surgery?
4. Where are medical graduates practising and why?
5. Where the brain organizes actions
6. Where we change our mind
7. Where your brain wires itself to like (name your favorite brand)
8. Where lifes memories are stored
9. Future therapies for stroke may block cell death
10. Antifolate therapies found effective against certain type of malaria
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where new therapies work best

(Date:12/20/2014)... December 20, 2014 Recently, AngelWeddingDress.com has ... Discount ”) for the coming Christmas. In the promotion, ... 80% off. , “We have something special for the ... the holiday season. Moreover, our new collections of 2015 ... are offered now at greatly discounted prices. Visit our ...
(Date:12/20/2014)... 2014 Today, Balfleet.com, one of the ... Sale, offering 50%-70% off on its Mother of ... The mother of the bride dresses from Balfleet.com feature ... 24/7 accessible and takes pride in providing high quality ... are offering great discounts on our mother of the ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 2014 These vanadium reserves are mostly ... Around 151,000 tons of vanadium were produced globally in ... usage increased at 6.7% AAGR during the period from ... industry, being the largest consumer, accounted for more than ... titanium-vanadium alloy and the chemical industry. , View Full ...
(Date:12/19/2014)... 2014 (HealthDay News) -- The intestinal bacteria that cause ... colitis, may be inherited, researchers report. The findings, ... could help in efforts to prevent the disease and ... the study authors added. "The intestinal bacteria, or ... can have a big impact on your health for ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
Cached News: